Pfizer-BioNTech’s Omicron Boosters Show Improved Immune Response
Pfizer-BioNTech recently announced results from an analysis assessing the immune response induced by the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine against newer Omicron sublineages. The data from this analysis indicated that the companies’ bivalent vaccine elicits a better increase in neutralizing antibody titers than the companies’ original COVID-19 vaccine against emerging Omicron sublineages. Read more.
|
Scientists Explore a 20-Subtype mRNA Influenza Vaccine According to researchers from the Perelman School of Medicine at the University of Pennsylvania, an experimental mRNA-based vaccine against all 20 known subtypes of the influenza virus provided extensive protection from otherwise lethal strains to initial test and therefore may one day serve as a universal preventative measure against a future influenza pandemic. Learn more about this upcoming vaccine.
|